1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
Systemic Lupus Erythematosus and Lupus Nephritis: Epidemiology Forecast to 2028

Systemic Lupus Erythematosus and Lupus Nephritis: Epidemiology Forecast to 2028

  • January 2020
  • 57 pages
  • ID: 5872289
  • Format: PDF
  • GlobalData
Up to $2996 off Until Sep 30th 2020

Summary

Table of Contents

Search Inside

Systemic Lupus Erythematosus and Lupus Nephritis: Epidemiology Forecast to 2028

Summary
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of multifactorial origin that can affect any organ or organ system, resulting in a broad spectrum of clinical manifestations ranging from dermatological involvement to multi-organ failure with episodes of relapses and remissions. Because of its dynamic nature, this disease has an unpredictable natural course leading to high rates of morbidity and even death (Bertsias, Cervera and Boumpas, 2012; Bhattacharya et al., 2011). Lupus nephritis (LN) or lupus glomerulonephritis is a complication of SLE in which the kidneys are affected. LN is a major contributor to morbidity and mortality among SLE patients (Bhattacharya et al., 2011; O’Neill and Cervera, 2010).

Epidemiologists utilized historical data obtained from peer-reviewed articles and reports to build the forecast for the diagnosed incident cases and the diagnosed prevalent cases of SLE and LN in the 7MM. Epidemiologists applied the incidence and prevalence of SLE and LN drawn from the above sources to each country’s population to calculate the number of estimated diagnosed incident cases and diagnosed prevalent cases for SLE and LN.

The following data describes the epidemiology of SLE and LN. In the 7MM, Epidemiologists forecast an increase in the diagnosed prevalent cases of SLE from 571,021 cases in 2018 to 600,663 cases in 2028, at an Annual Growth Rate (AGR) of 0.52%. When examining the AGR of diagnosed prevalence of SLE in individual markets, Epidemiologists forecast that the UK will see the highest AGR of 0.79% during the forecast period, while Germany will show the lowest negative AGR of 0.12%. In 2018, the 7MM had 98,620 diagnosed prevalent cases of LN, expected to increase to 102,939 diagnosed prevalent cases by 2028, at an AGR of 0.44%.

Scope
- The Systemic Lupus Erythematosus and Lupus Nephritis Epidemiology Report provides an overview of the risk factors and global trends of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- This report includes a 10-year epidemiological forecast of the diagnosed incident and diagnosed prevalent cases of SLE segmented by age, and sex, and the diagnosed prevalent cases are further segmented by severity.
- The report also includes a 10-year epidemiological forecast for various comorbidities of SLE. An epidemiological forecast of the diagnosed incident and diagnosed prevalent cases of LN among pediatric population and adult population for the 7MM is also incorporated.
- Additionally, the report includes the diagnosed prevalent cases of LN segmented by World Health Organization (WHO) and International Society of Nephrology (ISN)/Renal Pathology Society (RPS) classification into Classes I-VI.
- The SLE and LN epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
- The Epidemiology report is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the report supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy
The SLE and LN Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global SLE and LN markets.
- Quantify patient populations in the global SLE and LN markets to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SLE and LN therapeutics in each of the markets covered.
- Understand magnitude of SLE and LN population by its severity.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
25% Off

($3995)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on